← Natera overview
Natera IncNTRA

Why is Natera (NTRA) moving?

Q3 2026
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

July 2026
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

Latest
▲3

Natera's Record Q2, Raised Guidance, and EU Certification Drive Momentum

  • EU IVDR Class C Certification for Signatera Natera's Signatera test secured EU Class C certification under IVDR, ensuring continued market access in Europe beyond 2028. This strengthens regulatory standing and supports clinical trial adoption, which investors see as key to sustaining revenue growth.

    This is a new regulatory milestone that directly supports Signatera's European market position and future revenue.

  • Record Q2 Revenue and Raised 2026 Guidance Natera reported Q2 revenue of $753 million, up 38% year-over-year, with record test volumes and raised full-year guidance to $2.85–$2.91 billion. Gross margin improved to 65%, and Signatera's average selling price rose, signaling strong pricing power and operational scaling.

    This is the core financial update that shows accelerating growth and improved profitability, directly driving the stock's recent rally.

  • New Trial Collaboration for Latitude Test Natera announced a collaboration to use its Latitude MRD test in a Phase 1 trial for Kupando's immunotherapy candidate. This expands clinical use and validates the test's potential in new cancer indications, supporting long-term demand.

    This is a new business development that broadens the clinical application of Natera's products.

  • Druckenmiller's Continued Confidence vs. Valuation and Insider Selling Stanley Druckenmiller's family office holds Natera as its top position, worth about $865 million, reflecting strong institutional confidence. However, the stock trades at 16 times sales, insiders are selling, and the company remains unprofitable, which could cap upside.

    This highlights the key counterweight: strong investor backing but high valuation and profitability concerns.

Q2 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

June 2026
▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

▲3

Natera's Signatera Wins Guideline, Japan Approval; Trial Deals Expand Use

  • NCCN guideline recommends Signatera for bladder cancer NCCN, which sets US cancer treatment standards, now recommends Signatera for muscle-invasive bladder cancer. This should drive more doctors to order the test, boosting revenue. It's the first such recommendation for this cancer type.

    This is a major new regulatory/guideline endorsement that expands the market for Natera's flagship test.

  • Japan approves Signatera for colorectal cancer Japan's drug regulator approved Signatera for colorectal cancer, the first MRD test approved there. Natera plans to launch by end of 2026. Japan diagnoses over 150,000 colorectal cancer cases yearly, a large new market.

    This opens a major new geographic market for Signatera, directly increasing potential revenue.

  • New trial partnerships expand Signatera and Prospera use Natera signed deals to use Signatera in CytoDyn's colorectal cancer trial and Aveta's head and neck cancer trial, and Prospera in Eledon's kidney transplant trial. These generate revenue and build evidence for broader adoption.

    These partnerships show growing adoption of Natera's tests in drug development, supporting future revenue and clinical credibility.

© 2026 MarketDXWhy